Predictive factors of nivolumab plus ipilimumab treatment efficacy in metastatic renal cell carcinoma patients

被引:0
作者
Ohba, Kojiro [1 ]
Nakanishi, Hiromi [1 ]
Kawada, Ken [1 ]
Nakamura, Yuichiro [1 ]
Mitsunari, Kensuke [1 ]
Matsuo, Tomohiro [1 ]
Mochizuki, Yasushi [1 ]
Imamura, Ryoichi [1 ]
机构
[1] Nagasaki Univ Hosp, Dept Urol & Renal Transplantat, Sakamoto 1-7-1, Nagasaki, Nagasaki 8528501, Japan
关键词
renal cell carcinoma; nivolumab; ipilimumab; predictive factor; paraneoplastic symptom; C-REACTIVE PROTEIN; PROGNOSIS;
D O I
10.1093/jjco/hyae046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective Nivolumab plus ipilimumab is a recommended first-line therapy regimen for metastatic renal cell carcinoma. However, it is not clear which patient characteristics are associated with its effectiveness.Methods We retrospectively examined 67 metastatic renal cell carcinoma patients treated with nivolumab plus ipilimumab as a first-line therapy in multiple institutions from September 2018 to August 2022. We analyzed the relationships between survival outcomes and patient-related variables, including paraneoplastic symptoms. We also analyzed the relationships between changes in symptoms and parameters and outcomes.Results Of the 67 patients, 32 patients had paraneoplastic symptoms. The median progression-free survival was 14.9 months and median overall survival was 43.3 months. The objective response rate was 49.25% (33 patients), including two patients with complete response. Patients with cytoreductive nephrectomy, bone metastasis, high C-reactive protein levels and paraneoplastic symptoms were significantly correlated with short progression-free survival in the univariate analysis. Multivariate analysis of these factors showed that the presence of paraneoplastic symptoms at treatment initiation remained an independent predictor of progression-free survival. Of the 32 patients with paraneoplastic symptoms at treatment initiation, 12 patients had symptomatic improvement and 20 did not. The 1-year progression-free survival rates were significantly longer in improved patients compared with those with no improvement.Conclusions Patients without cytoreductive nephrectomy and with bone metastasis, liver metastasis, high C-reactive protein levels and paraneoplastic symptoms were significantly correlated with shorter progression-free survival. The presence of paraneoplastic symptoms was an independent predictor of progression-free survival. Improvement in paraneoplastic symptoms may reflect the treatment efficacy of nivolumab plus ipilimumab. Having paraneoplastic symptoms was an independent predictor of progression-free survival for the patients with metastatic renal cell carcinoma, and symptom improvement may reflect the treatment efficacy of nivolumab plus ipilimumab.
引用
收藏
页码:827 / 832
页数:6
相关论文
共 50 条
[21]   Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study [J].
Iinuma, Koji ;
Kameyama, Koji ;
Kawada, Kei ;
Fujimoto, Shota ;
Takagi, Kimiaki ;
Nagai, Shingo ;
Ito, Hiroki ;
Ishida, Takashi ;
Kawase, Makoto ;
Kawase, Kota ;
Nakai, Chie ;
Kato, Daiki ;
Takai, Manabu ;
Nakane, Keita ;
Koie, Takuya .
CURRENT ONCOLOGY, 2021, 28 (02) :1402-1411
[22]   Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma [J].
Hashimoto, Mamoru ;
Nakayama, Takahito ;
Fujimoto, Saizo ;
Inoguchi, Shunsuke ;
Nishimoto, Mitsuhisa ;
Kikuchi, Takashi ;
Adomi, Shogo ;
Banno, Eri ;
De Velasco, Marco A. ;
Saito, Yoshitaka ;
Shimizu, Nobutaka ;
Mori, Yasunori ;
Minami, Takafumi ;
Fujita, Kazutoshi ;
Nozawa, Masahiro ;
Nose, Kazuhiro ;
Yoshimura, Kazuhiro ;
Uemura, Hirotsugu .
ANTI-CANCER DRUGS, 2022, 33 (01) :E818-E821
[23]   Efficacy and Safety of Nivolumab With Ipilimumab in Elderly Patients With Advanced Renal Cell Carcinoma [J].
Ueda, Kosuke ;
Ito, Naoki ;
Sakai, Yuya ;
Ohnishi, Satoshi ;
Hirano, Taishi ;
Kurose, Hirofumi ;
Chikui, Katsuaki ;
Uemura, Keiichiro ;
Nishihara, Kiyoaki ;
Nakiri, Makoto ;
Suekane, Shigetaka ;
Igawa, Tsukasa .
ANTICANCER RESEARCH, 2024, 44 (11) :5087-5093
[24]   The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcoma [J].
Kalofonou, Foteini ;
Napolitano, Andrea ;
Benson, Charlotte ;
Miah, Aisha ;
Zaidi, Shane ;
Lindsay, Daniel ;
Thway, Khin ;
Jones, Robin L. .
RARE TUMORS, 2024, 16
[25]   Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma [J].
Savarapu, Pramod ;
Abdelazeem, Basel ;
Isa, Sakiru ;
Kesari, Kavitha ;
Kunadi, Arvind .
JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2021, 11 (06) :874-876
[26]   Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy [J].
Takagi, Toshio ;
Yoshida, Kazuhiko ;
Kondo, Tsunenori ;
Fukuda, Hironori ;
Ishihara, Hiroki ;
Kobayashi, Hirohito ;
Iizuka, Junpei ;
Ishida, Hideki ;
Tanabe, Kazunari .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (12) :1744-1750
[27]   The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma [J].
Ornstein, Moshe C. ;
Rini, Brian I. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (06) :577-584
[28]   An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma [J].
Zarrabi, Kevin ;
Wu, Shenhong .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (06) :695-705
[29]   Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab [J].
Nakayama, Takayuki ;
Takeshita, Hideki ;
Kagawa, Makoto ;
Washino, Satoshi ;
Shirotake, Suguru ;
Miura, Yuji ;
Hyodo, Yoji ;
Izumi, Keita ;
Inoue, Masaharu ;
Matsuoka, Yoh ;
Miyagawa, Tomoaki ;
Oyama, Masafumi ;
Saito, Kazutaka ;
Kawakami, Satoru .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) :1528-1537
[30]   The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy [J].
Numakura, Kazuyuki ;
Sekine, Yuya ;
Osawa, Takahiro ;
Naito, Sei ;
Tokairin, Ojiro ;
Muto, Yumina ;
Sobu, Ryuta ;
Kobayashi, Mizuki ;
Sasagawa, Hajime ;
Yamamoto, Ryohei ;
Nara, Taketoshi ;
Saito, Mitsuru ;
Narita, Shintaro ;
Akashi, Hideo ;
Tsuchiya, Norihiko ;
Shinohara, Nobuo ;
Habuchi, Tomonori .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, :1019-1026